Search Within

Advanced Practice Providers

  1. "Myeloma"
Formats
  1. Meeting Abstract (29)
  2. Journal Article (13)
Groups
  1. Center for Hematologic Malignancies (42)
  2. Department of Medicine (42)
  3. Hematologic Malignancies, Division of (42)
  4. Myeloma (42)
  5. Hematologic Malignancies Research (38)
  6. Nursing (37)

More Groups

People
  1. Alexander Lesokhin (25)
  2. Sergio Giralt (24)
  3. Sham Mailankody (24)
  4. Gunjan Shah (21)
  5. Heather Landau (19)
  6. Hani Hassoun (18)

More People

Years
  1. 2024 (2)
  2. 2023 (1)
  3. 2022 (1)
  4. 2021 (4)
  5. 2020 (6)
  6. 2019 (6)

More Years

Publications
  1. Blood (19)
  2. Biology of Blood and Marrow Transplantation (5)
  3. Journal of Clinical Oncology (3)
  4. New England Journal of Medicine (3)
  5. Blood Advances (2)
  6. JAMA Oncology (2)

More Publications

Publishers
  1. American Society of Hematology (21)
  2. Elsevier Inc. (7)
  3. American Society of Clinical Oncology (3)
  4. Massachusetts Medical Society (3)
  5. American Association for Cancer Research (2)
  6. American Medical Association (2)

More Publishers

Results (42)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy
    Journal Article

    Naidoo, J.; Wang, X.; Woo, K. M.; Iyriboz, T.; Halpenny, D.; Cunningham, J.; Chaft, J. E.; Segal, N. H.; Callahan, M. K.; Lesokhin, A. M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1
    Journal Article

    Naidoo, J.; Schindler, K.; Querfeld, C.; Busam, K.; Cunningham, J.; Page, D. B.; Postow, M. A.; Weinstein, A.; Lucas, A. S.; Ciccolini, K. T.; more...
    Cancer Immunology Research (2016)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Sznol, M.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Atkins, M. B.; Kirkwood, J. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status in a phase 1 trial of nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Kluger, H.; Sznol, M.; Callahan, M.; Postow, M.; Gordon, R.; Segal, N. H.; Rizvi, N.; Lesokhin, A.; Atkins, M. B.; Kirkwood, J.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-programmed death-1) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Sznol, M.; Kluger, H.; Callahan, M. K.; Postow, M. A.; Gordon, R.; Seal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Atkins, M. B.; Kirkwood, J. M.; more...
    Asia-Pacific Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL)
    Meeting Abstract

    Wolchok, J. D.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Reed, K.; Burke, M. M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Nivolumab plus Ipilimumab in advanced melanoma
    Journal Article

    Wolchok, J. D.; Kluger, H.; Callahan, M. K.; Postow, M. A.; Rizvi, N. A.; Lesokhin, A. M.; Segal, N. H.; Ariyan, C. E.; Gordon, R. A.; Reed, K.; more...
    New England Journal of Medicine (2013)

    Fulltext@MSK | Save
  • Immunologic correlates of the abscopal effect in a patient with melanoma
    Journal Article

    Postow, M. A.; Callahan, M. K.; Barker, C. A.; Yamada, Y.; Yuan, J.; Kitano, S.; Mu, Z.; Rasalan, T.; Adamow, M.; Ritter, E.; more...
    New England Journal of Medicine (2012)

    Fulltext@MSK | Save
  • Cost analysis of using plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for autologous stem cell mobilization in multiple myeloma patients treated at Memorial Sloan-Kettering Cancer Center (MSKCC)
    Meeting Abstract

    Adel, N. G.; Duck, E.; Collum, K.; Mccullagh, E.; Reich, L.; Landau, H.; Giralt, S.; Hassoun, H.
    Blood (2011)

    Fulltext@MSK | Save
  • High number of successful mobilizations associated with the use of plerixafor and colony stimulating factors in patients with multiple myeloma (MM) and lymphoma treated at Memorial Sloan-Kettering Cancer Center
    Meeting Abstract

    Adel, N. G.; Mathew, S.; Harnicar, S. J.; Mccullagh, E.; Landau, H.; Giralt, S.; Vanak, J.; Chimento, D.; Lucarelli, C.; Matasar, M. J.; more...
    Blood (2010)

    Fulltext@MSK | Save